The expanding role of therapeutic antibodies.
Therapeutic antibodies have been used since the end of nineteenth century, but their use is progressively increased and recently, with the availability of monoclonal antibodies, they are successfully employed in a large disease spectrum, which transversally covers different fields of medicine. Hyperimmune polyclonal immune globulin has been used against infectious diseases, in a period in which anti-microbial drugs were not yet available, and it still maintains a relevant place in prophylaxis/therapy. Although immune globulin should be considered life-saving as replacement therapy in humoral immunodeficiencies, its place in the immune-modulating treatment is not usually first-choice, but it should be considered as support to standard approved treatments. Despite therapeutic monoclonal antibodies have been lastly introduced in therapy, their extreme potentiality is reflected by the large number of approved molecules, addressed toward different immunological targets and able to heavily influence the prognosis and quality of life of a wide range of different diseases.
Sapienza Università di Roma -Facoltà di Medicina e Psicologia , Azienda Ospedaliera S. Andrea, Roma , Italy.
Simonetta
S
Salemi
Milica
M
Markovic
Gabriella
G
Martini
Raffaele
R
D'Amelio
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology / Q000628:therapy*; D007136:Immunoglobulins / Q000627:therapeutic use*; D056747:Immunomodulation; D007167:Immunotherapy / Q000639:trends
D000906:Antibodies; D000911:Antibodies, Monoclonal; D007136:Immunoglobulins
intravenous immune globulin; passive immunization; subcutaneous immune globulin; therapeutic monoclonal antibodies